Evidence that GZ proteins couple to hypothalamic 5-HT1A receptors in vivo by Serres, F. et al.
Evidence That Gz-Proteins Couple to Hypothalamic 5-HT1A
Receptors In Vivo
F. Serres, Q. Li, F. Garcia, D. K. Raap, G. Battaglia, N. A. Muma, and L. D. Van de Kar
Department of Pharmacology, Stritch School of Medicine, Loyola University of Chicago, Maywood, Illinois 60153
Using in situ hybridization and immunoblot analysis, the present
studies identified Gz mRNA and Gz-protein in the hypothalamic
paraventricular nucleus. The role of Gz-proteins in hypotha-
lamic 5-HT1A receptor signaling was examined in vivo. Activa-
tion of 5-HT1A receptors increases the secretion of oxytocin
and ACTH, but not prolactin. Intracerebroventricular infusion
(3–4 d) of Gz antisense oligodeoxynucleotides, with different
sequences and different phosphorothioate modification pat-
terns, reduced the levels of Gz-protein in the hypothalamic
paraventricular nucleus, whereas missense oligodeoxynucle-
otides had no effect. Neither antisense nor missense oligode-
oxynucleotide treatment altered basal plasma levels of ACTH,
oxytocin, or prolactin, when compared with untreated controls.
An antisense-induced decrease in hypothalamic Gz-protein lev-
els was paralleled by a significant decrease in the oxytocin and
ACTH responses to the 5-HT1A agonist 8-hydroxy-
dipropylamino-tetralin (8-OH-DPAT). In contrast, the prolactin
response to 8-OH-DPAT (which cannot be blocked by 5-HT1A
antagonists) was not inhibited by Gz antisense oligode-
oxynucleotides. Gz-proteins are the only members of the Gi /
Go-protein family that are not inactivated by pertussis toxin. In
a control experiment, pertussis toxin treatment (1mg/5 ml, i.c.v.;
48 hr before the 8-OH-DPAT challenge) did not inhibit the ACTH
response, potentiated the oxytocin response, and eliminated
the prolactin response to 8-OH-DPAT. Thus, pertussis toxin-
sensitive Gi /Go-proteins do not mediate the 5-HT1A receptor-
mediated increase in ACTH and oxytocin secretion. Combined,
these studies provide the first in vivo evidence for a key role of
Gz-proteins in coupling hypothalamic 5-HT1A receptors to ef-
fector mechanisms.
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Heterotrimeric guanine-nucleotide-binding proteins (G-proteins)
transduce extracellular signals to intracellular messengers. Gz-
protein is a member of the Gi-protein family with a 41–67% of
sequence homology with Gi- and Go-proteins (Fong et al., 1988;
Matsuoka et al., 1988). Unlike the other members of the Gi-
protein family, Gz-protein lacks the cysteine residue in the C
terminus that serves as the substrate for pertussis toxin-catalyzed
ADP ribosylation (Casey et al., 1990). This lack of a cysteine
residue makes Gz-protein the only member of the Gi/o-protein
family known to be insensitive to pertussis toxin and provides a
valuable means to identify the involvement of Gz-protein in
physiological responses. In vitro studies indicate that 5-HT1A
receptors are coupled to members of the Gi/Go-protein family,
including the pertussis toxin-sensitive Gi1-, Gi2-, Gi3-, and Go-
proteins, and the pertussis toxin-insensitive Gz-protein (Butkerait
et al., 1995; Albert et al., 1996; Barr et al., 1997). Gz-protein is
involved in 5-HT1A receptor-mediated inhibition of adenylyl cy-
clase in Sf9 cells (Butkerait et al., 1995; Barr et al., 1997). In spite
of extensive in vitro studies, little is known about the nature of the
receptors that couple to Gz-proteins in vivo. It is still unknown
which G-proteins couple hypothalamic 5-HT1A receptors to the
secretion of ACTH and oxytocin. The present studies investi-
gated the possible coupling of Gz-proteins to 5-HT1A receptor
signaling in the hypothalamus in vivo.
Neuroendocrine challenges provide a noninvasive approach to
study the responsivity of hypothalamic postsynaptic 5-HT1A re-
ceptors in vivo (Cowen, 1998). Serotonergic nerve terminals make
synaptic connections with oxytocin and corticotropin releasing
hormone (CRH)-containing neurons in the paraventricular nu-
cleus of the hypothalamus (Liposits et al., 1987; Saphier, 1991;
Kawano et al., 1992). Neurons in the paraventricular nucleus
express 5-HT1A receptors (Li et al., 1997a). Activation of 5-HT1A
receptors by a 5-HT1A agonist, such as 8-hydroxy-dipropylamino-
tetralin (8-OH-DPAT), induces an increase in oxytocin and CRH
secretion (Calogero et al., 1989; Bagdy, 1996). CRH subsequently
stimulates the secretion of ACTH from the pituitary gland into
the circulation. The ACTH and oxytocin responses to 8-OH-
DPAT can be inhibited by the selective 5-HT1A antagonist WAY-
100,635 (Vicentic et al., 1998). In contrast with ACTH and
oxytocin, the prolactin response to 8-OH-DPAT is not blocked by
5-HT1A antagonists, indicating that prolactin secretion induced
by 8-OH-DPAT is mediated by other receptors (Aulakh et al.,
1988; Vicentic et al., 1998). Therefore, in the present studies,
plasma ACTH and oxytocin levels were used as peripheral indi-
ces of hypothalamic 5-HT1A receptor function. As a negative
control, ACTH and oxytocin responses to 8-OH-DPAT were
compared with that of prolactin.
Initially, the expression of Gz mRNA and Gz-protein in the
hypothalamic paraventricular nucleus was examined using in situ
hybridization and immunoblot analysis, respectively. Subse-
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quently, two approaches were used to examine the functional role
of Gz-proteins in 5-HT1A receptor-mediated hormone secretion:
(1) an antisense strategy to specifically reduce the level of Gz-
protein in the hypothalamic paraventricular nucleus and (2) in-
tracerebroventricular pretreatment with pertussis toxin. In both
experiments, rats were challenged with the 5-HT1A agonist
8-OH-DPAT to test whether the physiological responses triggered
by activation of hypothalamic 5-HT1A receptors are mediated by
Gz-protein.
MATERIALS AND METHODS
Animals
Male Sprague Dawley rats (225–275 gm) were purchased from Harlan
(Indianapolis, IN). The rats were housed two per cage in lighting- (12 hr
light /dark: lights on at 7:00 A.M.), humidity-, and temperature-controlled
conditions. Food and water were available ad libitum. All procedures
were conducted in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals as approved by the
Loyola University Institutional Animal Care and Use Committee.
Drugs
HPLC-purified oligodeoxynucleotides were purchased from Genosys
Biotechnologies (The Woodlands, TX). Pertussis toxin was purchased
from Sigma (St. Louis, MO). (6)8-OH-DPAT HBr was purchased from
Research Biochemicals (Natick, MA). All drugs were dissolved in saline.
Pertussis toxin was intracerebroventricularly injected in a volume of 5 ml.
Two experiments with antisense oligodeoxynucleotides were designed
because the first experiment revealed a nonspecific toxicity of the phos-
phorothioate Gz antisense oligodeoxynucleotides. In the first experi-
ment, the sequence of Gaz antisense corresponding to nucleotide se-
quence 308–323 was 59-TCGTAGGCACGGTCA, and the sequence for
missense was 59-CTGCAGGTATGGCTA. These 15 mer oligode-
oxynucleotides were phosphorothioate-modified at all positions to delay
their degradation and were infused using Alzet osmotic minipumps for
3 consecutive days. Because the first batch of antisense oligodeoxynucle-
otide produced a reduction in Gz-, Gi1- and Gi2-protein levels in the
paraventricular nucleus, in the second experiment, the (33 base) Gaz
antisense oligodeoxynucleotide was modified to correspond to nucleotide
sequence 330–363. The sequence was 59-CGTGATCTCACCCTTGC-
TCTCTGCCGGGCCAGT-39, and the oligodeoxynucleotide was only
phosphorothioate-modified at the two bases of each end (59-CG and
GT-39) (Sanchez-Blazquez et al., 1995). The sequence of the missense
oligodeoxynucleotide was 59-CCCTTATTTACTTTCGCC-39, and it
was phosphorothioate modified at positions 59-CC and GC-39 (Sanchez-
Blazquez et al., 1995). In all experiments, saline or 8-OH-DPAT were
injected subcutaneously in a volume of 1 ml/kg.
Surgery
After several days of adaptation to their home cage, intracerebroventric-
ular cannulae were implanted in the rats by stereotaxic surgery. For the
Gz antisense experiment, rats were anesthetized with xylazine (6.7 mg/
kg)-ketamine (100 mg/kg). An L-shaped cannula (Plastics One,
Roanoke, VA) was implanted into the third cerebral ventricle at stereo-
taxic coordinates 1.5 mm caudal and 0.0 mm lateral with respect to
bregma and 9.5 mm ventral from the skull surface. Positioning the tip of
the cannula in the third ventricle instead of inside the paraventricular
nucleus was intended to spare the neurons from mechanical damage.
Damage to hypothalamic neurons would produce a reduced hormone
response to the 5-HT1A agonist, which could be misinterpreted as a
reduction in receptor coupling. A stainless steel obturator ensured that
the cannula would stay patent. The cannulae were kept in place by dental
cement attached to miniscrews embedded in the skull. The rats received
a subcutaneous injection of saline (1 ml) and ampicillin (50 mg/kg, s.c.)
after surgery to prevent dehydration and infection, respectively, and were
returned to their home cage. The position of the cannula tracks was
carefully verified in each animal when the brains were subsequently
sectioned in a cryostat. The procedures for the pertussis toxin experi-
ment were similar except that a cannula was implanted in the lateral
cerebral ventricle (0.5 mm caudal, 1.4 mm lateral from bregma and 4.5
mm ventral to the surface of the skull).
Experimental protocols
Gz antisense experiment
At least 10 d after cannula implantation, rats were randomly assigned to
groups that received either missense or antisense oligodeoxynucleotides.
Untreated animals were used as controls to verify for nonselective
toxicity of the nucleotides.
First antisense experiment. Osmotic mini-pumps (Alzet model 1003; Alza,
Palo Alto, CA) were used for chronic microinfusions of the 15 mer
phosphorothioate modified Gaz antisense oligodeoxynucleotides (0.426
mg/ml; 0.093 nmol/ml), or missense oligodeoxynucleotides (0.426 mg/ml;
0.095 nmol/ml) into the third ventricle, allowing a sustained delivery at a
rate of 1 ml /hr for 3 d. The osmotic minipumps were implanted subcu-
taneously between the scapulae under halothane anesthesia and con-
nected to the cannulae with silicone rubber tubing (Plastics One). The
incisions were closed with sterile clips, and the rats were returned to their
home cage. On the fourth day, the rats received an injection of either
saline (1 ml/kg, s.c.) or 8-OH-DPAT (50 mg/kg, s.c.) and were decapi-
tated 15 min after the injection. Trunk blood was collected in tubes
containing 0.5 ml of a 0.3 M EDTA, pH 7.4, solution and centrifuged at
4°C. Plasma aliquots were stored at 270°C until they were used for
hormone radioimmunoassays. The brains were removed and rapidly
frozen with dry ice, then stored at 270°C for the microdissection of the
hypothalamic paraventricular nucleus.
Second antisense experiment. Osmotic minipumps (Alzet model 2001;
Alza) were used for chronic microinfusions of Gaz antisense oligode-
oxynucleotides or missense oligodeoxynucleotides (0.2083 nmol/ml) into
the third ventricle, allowing a sustained delivery at a rate of 1 ml /hr for
4 d. The dose was increased approximately twofold (compared with the
first experiment) to compensate for the higher vulnerability to degrada-
tion of the nucleotides, which are only modified at the two bases on each
end of the molecule. The osmotic minipumps were implanted between
the scapulae under halothane anesthesia and connected to the cannulae
with silicone rubber tubing (Plastics One). The incisions were closed with
sterile clips, and the rats were returned to their home cage. On the fifth
day, the rats received an injection of either saline (1 ml/kg, s.c.) or
8-OH-DPAT (50 mg/kg, s.c.) and were decapitated 15 min after the
injection. Trunk blood was collected as described for experiment 1, and
plasma aliquots were stored at 270°C until they were used for hormone
radioimmunoassays. The brains were removed and rapidly frozen with
dry ice, then stored at 270°C for the microdissection of the hypothalamic
paraventricular nucleus.
Pertussis toxin experiment
At least 10 d after surgical implantation of the cannulae, the rats received
5 ml (intracerebroventricularly) of either saline or pertussis toxin (0.2
mg/ml; total of 1 mg/5 ml) through the cannulae and were returned to their
home cage. Forty-eight hours later, the rats were challenged with saline
or 8-OH-DPAT (50 mg/kg, s.c.) and were decapitated 15 min after the
injection. Trunk blood was collected in tubes containing 0.5 ml of a 0.3 M
EDTA, pH 7.4, solution and centrifuged at 4°C. Plasma aliquots were
stored at 270°C until they were used for hormone radioimmunoassays.
Molecular and biochemical assays
In situ hybridization
Gz mRNA was examined in cells in the hypothalamic paraventricular
nucleus using in situ hybridization. The brain was removed and blocked,
frozen, and stored at 270°C. Ten-micrometer-thick sections were cut on
a cryostat and then fixed in 4% paraformaldehyde at 4°C. Using previ-
ously described methods (Muma et al., 1990), tissue sections (10 mm)
were rinsed and then acetylated in 0.25% acetic anhydride in 0.1 M
triethanolamine hydrochloride. After dehydration, tissue sections were
hybridized with 35S-labeled cDNA probes overnight at 37°C. The cDNA
probe for Gz was a generous gift from Dr. Yoshio Kaziro (Tokyo
Institute of Technology, Tokyo, Japan). The hybridization buffer con-
sisted of 50% formamide, 43 SSPE, Denhardt’s solution, 200 mg/ml
ssDNA and tRNA, and 20 mM dithiothreitol. Probes were labeled using
a Nick translation kit (Boehringer Mannheim, Mannheim, Germany).
Slides were washed in 13 SSC (150 mM sodium chloride and 15 mM
sodium citrate) at 50°C, dried, and dipped in NTB2 (Eastman Kodak,
Rochester, NY) nuclear emulsion. After incubation for 3–4 weeks, silver
grains were developed, fixed, and sections were stained with cresyl violet.
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Immunoblot analysis
Tissue dissection. Gaz-, Gai1-, and Gai2-protein levels were measured in
micropunches of the paraventricular nucleus of the hypothalamus. Rat
brains were placed in a cryostat at 210°C, and coronal sections were cut
to obtain a 700 mm section containing the paraventricular nucleus. Using
the diagram in Figure 1, the paraventricular nucleus was microdissected
from this section with the aid of a stereomicroscope.
Protein fractionation. All procedures were conducted at 4°C unless
otherwise indicated. Briefly, the tissues were homogenized in 0.5 ml of a
50 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 10% sucrose, and 0.5
mM phenylmethanesulfonyl fluoride (PMSF). After centrifugation at
20,000 3 g for 60 min, the pellets (containing the membrane-bound
proteins) were solubilized in a 20 mM Tris buffer, pH 8, containing 1 mM
EDTA, 100 mM NaCl, 0.1% sodium cholate, and 1 mM dithiothreitol in
a ratio of 3 ml of buffer per milligram of tissue. The resuspended
homogenates were incubated and shaken for 1 hr, followed by centrifu-
gation at 100,000 3 g for 60 min. The supernatant (containing the
membrane-bound G-proteins) was collected and stored for the determi-
nation of membrane-bound G-protein levels. Protein concentrations
were measured according to Lowry et al. (1951) using bovine serum
albumin as a standard.
Quantification of G-proteins. The solubilized proteins (1.6 mg/ lane)
were resolved by SDS-PAGE, using 0.75-mm-thick Tris-glycine denatur-
ing reducing gels, containing 0.1% SDS, 12.5% acrylamide/bisacrylamide
(30:0.2), 4.6 M urea, and 375 mM Tris, pH 8.7 (Mullaney and Miligan,
1990). The proteins were then electrophoretically transferred for 2 hr to
nitrocellulose membranes, which were then allowed to dry. The mem-
branes were incubated at room temperature in a solution containing 5%
nonfat dry milk, 0.05% NP-40, 50 mM Tris, and 150 mM NaCl, pH 7.4, for
1 hr and were then washed. The membranes were incubated with poly-
clonal antisera for Gz (I-20; Santa Cruz Biotechnology, Santa Cruz, CA;
1:6000 dilution) or Gi1/2 (AS/7; DuPont NEN, Boston, MA; 1:2500
dilution), at 4°C overnight. Membranes were then incubated at room
temperature with a secondary antibody (goat anti-rabbit serum; Organon
Teknika Cappel, Durham, NC; 1:5000 dilution) for 60 min. After four
washes with 0.05% NP-40 in 50 mM Tris and 150 mM NaCl, the mem-
branes were incubated with rabbit peroxidase–antiperoxidase (Organon
Teknika Cappel; 1:10,000) for 1 hr. The membranes were incubated with
the ECL chemiluminescence substrate solution (Amersham, Arlington
Heights, IL) for 1 min and then exposed to Kodak x-ray film for 10–60 sec.
G-protein data analysis. Films were analyzed densitometrically using
NIH Image (version 1.57) for Macintosh computers. The gray scale
density readings were calibrated using a transmission step wedge stan-
dard. The integrated optical density (IOD) of each band was calculated
as the sum of optical densities of all the pixels within the area of the band
outlined. An area adjacent to the G-protein bands was used to calculate
the background optical density of the film. The IOD for the film back-
ground was subtracted from the IOD for each band. The resulting IOD
for each G-protein band was then divided by the amount of protein
loaded on the corresponding lane. Three samples from each treatment
group and three randomly selected control samples were loaded on each
gel. Each sample was measured on three independent gels. To control for
intergel variability, a mean IOD per microgram of protein was obtained
from the three controls on each gel. To determine the relative amounts
of the G-proteins per sample, the IOD per microgram of protein value
for each sample was divided by the mean IOD per microgram of protein
value obtained from control samples on the same gel. Data for each rat
were expressed as “% of control.” Because tissue samples were measured
on three independent gels, the mean % of control obtained from the
three gels represented the data for each rat.
Radioimmunoassays
Plasma ACTH and prolactin were measured by radioimmunoassays as
detailed previously (Li et al., 1993). ACTH antiserum was purchased
from IgG Corporation (Nashville, TN). ACTH (1–39) standards were
obtained from Calbiochem (San Diego, CA). Bovine serum albumin and
aprotinin were purchased from Sigma. Normal rabbit serum and goat
anti-rabbit-g-globulin were purchased from Calbiochem. 125I-ACTH was
obtained from DiaSorin (Stillwater, MN). Kits for prolactin radioimmu-
noassay were provided by the National Institute of Arthritis, Diabetes,
Digestive, and Kidney Disorders (NIADDK). Plasma oxytocin was as-
sayed as detailed in our previous paper (Li et al., 1997b). For oxytocin
extraction from plasma, acetone (Spectranalyzed A-19) and petroleum
ether were obtained from Fisher Scientific (Pittsburgh, PA). The oxyto-
cin antiserum was a generous donation by Dr. Lanny Keil (Ames Re-
search Center, Sunnyvale CA). 125I-oxytocin was purchased from Du-
Pont NEN at a specific activity of 135 Ci/mmol.
Statistics
The data are presented as group means with the SEM values. The
G-protein data were analyzed by a one-way ANOVA, and group means
were compared by Newman–Keuls’ multiple range test (Steel and Torrie,
1960). The hormone data were analyzed by a two-way ANOVA, and
group means were compared by Newman–Keuls’ multiple range test
(Steel and Torrie, 1960). GB-STAT software (Dynamic Microsystems,
Silver Spring, MD) was used for all the statistical analyses.
RESULTS
In situ hybridization
Figure 2 shows a coronal section through the hypothalamus at a
high magnification of 3303 (A) and a dark-field picture of a lower
magnification (B). High grain density was observed in cells of the
hypothalamic paraventricular nucleus, indicating the expression
of mRNA encoding Gaz.
Gz antisense experiments
Figure 3A displays immunoblots of different amounts of homog-
enate obtained from microdissected tissue containing the hypo-
thalamic paraventricular nucleus. Loading increasing amounts of
protein resulted in increased IOD of the bands on the immuno-
blots. The levels of Gz-protein in the paraventricular nucleus are
sufficiently high to allow detection when 1.6 mg of total protein
was loaded on the gel.
Levels of Gz-protein
Figure 3B illustrates immunoblots of Gz-proteins obtained from
control rats and from rats treated with missense or antisense
oligodeoxynucleotides. Missense treatment did not result in a
Figure 1. Diagrammatic representation of the microdissection of the
hypothalamic paraventricular nucleus from coronal sections (700 mm).
The landmarks used to identify the coronal section are those seen at 1.8
mm caudal to bregma according to Paxinos and Watson (1986). F, Fornix;
PVN, paraventricular nucleus of the hypothalamus.
Figure 2. In situ hybridization of Gz mRNA in the hypothalamic para-
ventricular nucleus. A, High magnification (3303) of cells in the paraven-
tricular nucleus expressing Gz mRNA; B, dark-field low level magnifica-
tion of the hypothalamus.
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substantial reduction in the Gz-protein band, whereas treatment
with antisense oligodeoxynucleotides substantially decreased the
integrated optical density of the Gz band (Fig. 3B). In the first
experiment, treatment with 15 mer antisense oligodeoxynucleo-
tides that were phosphorothioate-modified at all positions pro-
duced a decrease (by 41%) in Gz-protein levels, compared with
untreated rats (F(2,23) 5 6.076; p , 0.01), whereas treatment with
missense oligodeoxynucleotides did not significantly reduce the
levels of Gz-proteins in the paraventricular nucleus (Table 1).
However, this antisense treatment also reduced the levels of Gi1
and Gi2-proteins (40–50%; Table 1), suggesting nonspecific
changes.
In a second experiment, we tested longer oligodeoxynucleo-
tides that were only phosphorothioate-modified at the two bases
on each end. Figure 4 shows the mean percent reduction in Gz-,
Gi1-, and Gi2-protein levels in the paraventricular nucleus. Anti-
sense treatment produced a decrease of 38.5% in Gz-protein
levels, compared with missense, and 41.2% compared with un-
treated rats (F(2,19) 5 4.1423; p , 0.05). Treatment with missense
oligodeoxynucleotides did not reduce the levels of Gz-proteins in
the paraventricular nucleus (Fig. 4). The levels of Gi1 and Gi2-
proteins were not reduced by either antisense or missense treat-
ments (Fig. 4).
Hormone responses to 8-OH-DPAT
In both experiments, basal levels of oxytocin, ACTH, and pro-
lactin were not significantly different among untreated, missense-
treated, and antisense-treated rats.
In the first antisense experiment, administration of 8-OH-
DPAT (50 mg/kg, s.c.) increased plasma oxytocin by 888% (Fig.
5A), ACTH by 693% (Fig. 5B), and prolactin by 118% (Fig. 5C)
in untreated rats. Treatment with 15 mer phosphorothioate-
modified Gz antisense oligodeoxynucleotides produced a signifi-
cant inhibition of the oxytocin response to 8-OH-DPAT, by 43%
compared with untreated controls, and by 35% compared with
missense-treated rats (Fig. 5A). The two-way ANOVA indicated
a significant main effect of treatment (F(2,46) 5 3.38; p , 0.05), a
significant main effect of 8-OH-DPAT (F(1,46) 5 101.8; p , 0.001),
and a significant interaction between 8-OH-DPAT and oligode-
oxynucleotide treatment (F(2,46) 5 3.796; p , 0.05). Post hoc
Newman–Keuls’ test indicated that the oxytocin response to
8-OH-DPAT is significantly decreased in antisense-treated rats
compared to missense-treated rats ( p , 0.05) and untreated rats
( p , 0.01).
Treatment with Gz antisense oligodeoxynucleotides also signif-
icantly decreased the ACTH response to 8-OH-DPAT, by 51%
compared to the missense group and by 42% compared with
untreated rats (Fig. 5B). The two-way ANOVA indicated no main
effect of antisense treatment (F(2,45) 5 2.30; p . 0.10), a signifi-
cant main effect of 8-OH-DPAT (F(1,45) 5 48.1; p , 0.0001), and
a significant interaction between oligodeoxynucleotide treatment
and 8-OH-DPAT (F(2,45) 5 3.27; p , 0.05). A post hoc Newman–
Keuls’ test indicated that the response to 8-OH-DPAT is signifi-
cantly decreased in Gz antisense-treated rats compared with
missense-treated rats ( p , 0.05).
Figure 3. A, Immunoblots showing the expression of Gz-proteins in the
hypothalamic paraventricular nucleus. The numbers below indicate the
amount of protein loaded on each lane of the gel. B, Immunoblots
demonstrating the changes in Gz-proteins in the hypothalamic paraven-
tricular nucleus after treatment with missense or Gz antisense
oligodeoxynucleotides.
Table 1. Effects of completely phosphorothioated, 15 mer missense and
Gz antisense oligodeoxynucleotides on the levels of Gz, Gi1, and Gi2
proteins in hypothalamic paraventricular nucleus “punches”
G-protein Uninjected Missense Antisense
Gz 101.3 6 8.8 76.7 6 12.6 52.4 6 8.7*
Gi1 101.8 6 22.6 101.0 6 28.1 45.1 6 8.9*
Gi2 107.6 6 15.1 102.3 6 21.1 46.3 6 4.8*
The data represent the mean 6 SEM (IOD/mg proteins as percentage of control)
obtained from 7–10 rats. *Significant reduction compared with the missense and
uninjected groups (one-way ANOVA and Newman–Keuls’ test).
Figure 4. Effect of Gz antisense oligodeoxynucleotides on the levels of
Gz-, Gi1-, and Gi2-proteins in the hypothalamic paraventricular nucleus.
The data represent the mean 6 SEM of seven or eight rats per group.
*Significant difference from the missense and uninjected group, p , 0.05
(one-way ANOVA and Newman–Keuls’ test).
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8-OH-DPAT significantly increased the plasma levels of pro-
lactin in untreated rats, missense-, and Gz antisense-treated rats
(Fig. 5C). The two-way ANOVA indicated no significant main
effect of the treatment (F(2,46) 5 0.29; p . 0.10), a main effect of
8-OH-DPAT (F(1,46) 5 30.929; p , 0.01), and no significant
interaction between oligonucleotide treatment and 8-OH-DPAT
(F(2,46) 5 0.0783; p . 0.10).
In the second antisense experiment, administration of 8-OH-
DPAT (50 mg/kg, s.c.), increased plasma oxytocin by 1274% (Fig.
6A), ACTH by 860% (Fig. 6B), and prolactin by 300% (Fig. 6C)
in untreated rats. The oxytocin response to 8-OH-DPAT was not
significantly different in missense-treated rats when compared to
untreated rats. However, treatment with the partly phosphoro-
thioate-modified 33 mer Gz antisense oligodeoxynucleotides re-
duced the oxytocin response to 8-OH-DPAT by 39% compared
with untreated controls and by 25% compared with missense-
treated rats (Fig. 6A). The two-way ANOVA indicated a signifi-
cant main effect of 8-OH-DPAT (F(1,31) 5 170.5; p , 0.001), a
significant main effect of treatment (F(2,31) 5 3.73; p , 0.05), and
a significant interaction between 8-OH-DPAT and oligode-
oxynucleotide treatment (F(2,31) 5 4.09; p , 0.05). A post hoc
Newman–Keuls’ test indicated that the oxytocin response to
8-OH-DPAT is significantly decreased in antisense-treated rats
compared to control rats ( p , 0.05).
Treatment with Gz antisense oligodeoxynucleotides also signif-
icantly decreased the ACTH response to 8-OH-DPAT, by 35%
compared to the missense group, and by 49% compared with
untreated rats (Fig. 6B). The two-way ANOVA indicated a sig-
nificant main effect of antisense treatment (F(2,31) 5 5.23; p ,
0.05), a significant main effect of 8-OH-DPAT (F(1,31) 5 109.8;
p , 0.0001), and a significant interaction between oligode-
oxynucleotide treatment and 8-OH-DPAT (F(2,31) 5 5.45; p ,
0.01). A post hoc Newman–Keuls’ test indicated that the response
Figure 5. Effect of completely phosphorothioate-modified 15 mer Gz
antisense oligodeoxynucleotides on the oxytocin (A), ACTH ( B), and
prolactin (C) responses to 8-OH-DPAT (50 mg/kg, s.c.). The data repre-
sent the mean 6 SEM of seven or eight rats per group. *Significant effect
of Gz antisense oligodeoxynucleotides, p , 0.01 (Newman–Keuls’ test).
Figure 6. Effect of partially phosphorothioate-modified 33 mer Gz anti-
sense oligodeoxynucleotides on the oxytocin ( A), ACTH (B), and pro-
lactin (C) responses to 8-OH-DPAT (50 mg/kg, s.c.). The data represent
the mean 6 SEM of seven or eight rats per group. *Significant effect of Gz
antisense oligodeoxynucleotides, p , 0.01 (Newman–Keuls’ test).
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to 8-OH-DPAT is significantly decreased in Gz antisense-treated
rats compared with missense-treated ( p , 0.05) and control rats
( p , 0.01).
8-OH-DPAT significantly increased the plasma levels of pro-
lactin in untreated, missense-treated, and Gz antisense-treated
rats (Fig. 6C). The two-way ANOVA indicated no significant
main effect of the treatment (F(2,30) 5 2.18; p . 0.1), a significant
main effect of 8-OH-DPAT (F(1,31) 5 41.51; p , 0.01), and no
significant interaction between oligodeoxynucleotide treatment
and 8-OH-DPAT (F(2,31) 5 2.09; p . 0.1).
Pertussis toxin experiment
Treatment with pertussis toxin also did not alter the basal plasma
levels of oxytocin (Fig. 7A). Injection of 8-OH-DPAT to vehicle-
pretreated rats increased plasma levels of oxytocin (by 963%; Fig.
7A). Pretreatment with pertussis toxin significantly potentiated
the oxytocin response to 8-OH-DPAT (by 206.4%; Fig. 7A). The
two-way ANOVA indicated no significant main effect of pertussis
toxin (F(1,31) 5 2.94; p . 0.05), a significant main effect of
8-OH-DPAT (F(1,31) 5 22.02; p , 0.0001), and no significant
interaction between pertussis toxin and 8-OH-DPAT (F(1,31)5
2.53; p . 0.1). However, a post hoc Newman–Keuls’ test indicated
that the oxytocin response to 8-OH-DPAT was significantly po-
tentiated in rats pretreated with pertussis toxin, when compared
with rats pretreated with vehicle ( p , 0.05).
Pretreatment with pertussis toxin did not alter the basal levels
of ACTH (Fig. 7B). Administration of 8-OH-DPAT to rats that
were pretreated with an intracerebroventricular injection of sa-
line significantly elevated plasma levels of ACTH (by 1031%).
The ACTH response to 8-OH-DPAT was not significantly af-
fected by treatment with pertussis toxin (Fig. 7B). The two-way
ANOVA indicated no significant main effect of pertussis toxin
(F(1,32) 5 0.95; p . 0.1), a significant main effect of 8-OH-DPAT
(F(1,32) 5 39.1; p , 0.0001), and no significant interaction be-
tween pertussis toxin and 8-OH-DPAT (F(1,32) 5 1.27; p . 0.1).
In contrast with its effects on ACTH and oxytocin, pertussis
toxin treatment significantly reduced the basal plasma levels of
prolactin (to 38.2% of control; Fig. 7C). 8-OH-DPAT also signif-
icantly increased the plasma levels of prolactin in rats that were
pretreated with vehicle (by 162%; Fig. 7C). Pretreatment with
pertussis toxin significantly blocked the 8-OH-DPAT-induced
elevation of plasma prolactin (Fig. 7C). The two-way ANOVA
indicated a significant main effect of pertussis toxin (F(1,30) 5
22.82; p , 0.0001), a significant main effect of 8-OH-DPAT
(F(1,30) 5 6.75; p , 0.05), but no significant interaction between
pertussis toxin and 8-OH-DPAT (F(1,30) 5 1.23; p . 0.1). The
post hoc Newman–Keuls’ test indicated that the prolactin re-
sponse to 8-OH-DPAT was significantly inhibited in rats pre-
treated with pertussis toxin when compared with rats pretreated
with vehicle ( p , 0.01).
DISCUSSION
This study provides functional in vivo evidence for the coupling of
Gz-proteins to 5-HT1A receptors in the hypothalamic paraven-
tricular nucleus. We have established that Gz mRNA and Gz-
protein are expressed in the hypothalamic paraventricular nu-
cleus and that an antisense oligodeoxynucleotide-induced
reduction in the levels of Gz-protein inhibits the ACTH and
oxytocin responses to a 5-HT1A agonist. These observations
suggest that Gz-proteins transduce signals from 5-HT1A receptors
to the secretion of ACTH and oxytocin.
Cotransfection experiments in cell lines indicate that Gz-
proteins can couple to a variety of receptors such as m- and
d-opioid, a2-adrenergic, dopamine-D2, adenosine-A1, and
5-HT1A receptors (Ho and Wong, 1998). However, because Gz-
protein is expressed in large quantities in these cell lines, coupling
of Gz-protein to a receptor subtype might not be of physiological
significance. Such studies have to be validated by in vivo
approaches.
8-OH-DPAT is the prototypical 5-HT1A agonist used in neu-
roendocrine research. It has a high affinity for 5-HT1A receptors
and a 10- to 100-fold lower affinity for other 5-HT receptor
subtypes (Hoyer et al., 1994; Jasper et al., 1997). The dose of
8-OH-DPAT was selected to be submaximal and close to its ED50
value to minimize activation of other receptors (Li et al., 1993).
Activation of 5-HT1A receptors stimulates the secretion of oxy-
tocin and CRH (Pan and Gilbert, 1992; Bagdy, 1998). Increased
Figure 7. Effect of pretreatment with pertussis toxin (1 mg, i.c.v.) on the
oxytocin (A), ACTH (B), and prolactin (C) responses to 8-OH-DPAT
(50 mg/kg, s.c.). The data represent the mean 6 SEM of 8–10 rats per
group. *Significant effect of pertussis toxin, p , 0.01 (Newman–Keuls’
test).
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release of CRH stimulates the secretion of ACTH from the
pituitary gland (Bagdy, 1998). The 8-OH-DPAT-induced eleva-
tion in plasma ACTH and oxytocin levels is inhibited by the
selective 5-HT1A antagonist WAY-100,635 (Vicentic et al., 1998).
In contrast, the prolactin response to 8-OH-DPAT is not antag-
onized by WAY-100,635, indicating that it is not mediated by
5-HT1A receptors (Vicentic et al., 1998). Therefore, prolactin
measurements provided a control for the selectivity of effects on
5-HT1A receptor signaling.
Antisense oligodeoxynucleotides are readily degraded (Morris
and Li, 1998). To increase their cellular stability, we used
phosphorothioate-modified oligodeoxynucleotides. Our initial ex-
periment, using oligodeoxynucleotides in which all bases were
phosphorothioate modified, resulted in a reduction in the levels
of Gz and a 40–50% inhibition of the oxytocin and ACTH
responses to 8-OH-DPAT, compared with the missense and
uninjected control groups. However, this sequence of
phosphorothioate-modified Gz antisense oligodeoxynucleotides
produced a reduction in both Gi1- and Gi2-protein levels. The
nonspecific effect of this antisense oligodeoxynucleotide is likely
attributable to its sequence, because the phosphorothioate-
modified missense oligodeoxynucleotide did not reduce the levels
of Gi1- or Gi2-proteins. Therefore, in a subsequent experiment,
we changed the sequence of the oligodeoxynucleotides, and only
the two bases at each end were phosphorothioate-modified.
These longer and less modified oligodeoxynucleotides were more
selective for Gz-protein because the levels of Gi1- and Gi2-
proteins in the paraventricular nucleus were not reduced. Fur-
thermore, the baseline levels of hormones were not different in
missense- or antisense oligodeoxynucleotide-treated groups,
compared with uninjected controls. Thus, both Gz antisense oli-
godeoxynucleotides have a common effect on the levels of Gz-
proteins and on the ACTH and oxytocin response to the 5-HT1A
agonist. The lack of significant reduction in Gz-protein level, in
missense-treated rats, was further confirmed by the lack of a
significant inhibition of the hormone responses to 8-OH-DPAT,
compared with the uninjected controls.
The decrease in Gz-protein levels, after antisense treatment,
induced a proportional inhibition of the oxytocin and ACTH
responses to 8-OH-DPAT. Oxytocin synthesizing cells are lo-
cated in the paraventricular nucleus and release oxytocin directly
into the bloodstream from the neurohypophysis. Therefore,
changes in plasma levels of oxytocin provide a direct and sensitive
indicator of changes in Gz-protein-coupled 5-HT1A receptor
function in the hypothalamus.
The data obtained using both antisense oligodeoxynucleotides
and pertussis toxin suggest that pertussis toxin-sensitive Gi/o-
proteins do not mediate 5-HT1A receptor-induced ACTH secre-
tion and that ACTH secretion is under the control of the pertus-
sis toxin-insensitive Gz-protein. ACTH secretion is amplified
because it is mediated by activation of CRH receptors, which are
coupled via G-proteins to effector enzymes. Therefore, any de-
crease in 5-HT1A receptor signaling could be masked by the
amplification by CRH of ACTH release. Consequently, the ob-
served decrease in ACTH would not be expected to reflect a
proportional decrease in 5-HT1A receptor systems in the para-
ventricular nucleus. The fact that Gz antisense oligodeoxynucle-
otide treatment produced an ;40% decrease of the ACTH
response to 8-OH-DPAT suggests a possibility of a much larger
decrease of 5-HT1A receptor function in CRH cells.
Pertussis toxin-sensitive G-proteins include members of the
Gi-protein family such as Gi1-, Gi2-, Gi3-, and Go-proteins (Hamm
and Gilchrist, 1996; Fields and Casey, 1997). Proteins insensitive
to pertussis toxin include Gq/11-, Gs-, and Gz-proteins (Fields and
Casey, 1997). 5-HT1A receptors have a very low affinity for Gs
and Gq/11-proteins (Butkerait et al., 1995; Albert et al., 1996), and
it is not likely that these G-proteins mediate the effect of 5-HT1A
receptors on the secretion of ACTH and oxytocin. To our knowl-
edge, all in vivo evidence reported to date suggests that, in other
brain regions such as the dorsal raphe and hippocampus, the
physiological effects of 5-HT1A receptor activation are mediated
by pertussis toxin-sensitive Gi/o-proteins (Clarke et al., 1987;
Innis and Aghajanian, 1987; Blier et al., 1993; Romero et al.,
1994).
In the present study, we used a relatively low dose (1 mg, i.c.v.)
of pertussis toxin to prevent its toxic side effects. However, this
pertussis toxin dose (1 mg, i.c.v.) is equal to or higher than doses
that were previously shown to affect physiological responses to
activation of other receptors that are coupled to Gi- and/or
Go-proteins, such as m-opioid receptors (Parolaro et al., 1990; Lin
and Pan, 1996), dopamine-D2 receptors (Okada et al., 1994), and
substance P receptors (Bot and Chahl, 1993). The failure of
pertussis toxin to inhibit the ACTH and oxytocin responses to
8-OH-DPAT, combined with the inhibition of the ACTH and
oxytocin responses to 8-OH-DPAT by Gz antisense oligode-
oxynucleotides, suggests that Gz-proteins are the key component
in 5-HT1A receptor signaling in the hypothalamic paraventricular
nucleus.
An unexpected finding was the oxytocin response to 8-OH-
DPAT, which was potentiated instead of reduced by pertussis
toxin. One explanation for this potentiated response is that other
receptors that are coupled to Gi- and/or Go-proteins inhibit the
secretion of oxytocin. For example, m-opioid receptors inhibit the
secretion of oxytocin (Pumford et al., 1993; Ingram et al., 1996).
Similar to our results, the opioid antagonist naloxone potentiated
the oxytocin response to another stimulus (systemic injection of
cholecystokinin) without altering basal oxytocin levels (Leng et
al., 1992). Another possible explanation is that hypothalamic
Gi/o-proteins compete with Gz-proteins for 5-HT1A receptor cou-
pling, but only Gz-proteins would mediate the effects on oxytocin
secretion. Inactivation of Gi/o-proteins by pertussis toxin would
thus allow an increased coupling efficiency of Gz-protein to
5-HT1A receptors, resulting in an enhanced secretion to the same
8-OH-DPAT dose.
We measured plasma prolactin levels as a control measure on
the specificity and effectiveness of our treatments. As mentioned
earlier, the effect of 8-OH-DPAT on the secretion of prolactin is
not exclusively mediated by 5-HT1A receptors and involves other,
as yet uncharacterized, mechanisms (Aulakh et al., 1988; Vicentic
et al., 1998). The injection of Gz antisense oligodeoxynucleotides
did not inhibit the prolactin response to 8-OH-DPAT, supporting
our conclusion that Gz-proteins specifically couple 5-HT1A recep-
tors to the stimulation of oxytocin and ACTH secretion.
The pertussis toxin-induced inhibition of basal as well as 8-OH-
DPAT-induced increase of prolactin release could be explained
as a consequence of increased activity of tuberoinfundibular
dopamine neurons. For example, receptors that are coupled to
pertussis toxin-sensitive Gi-proteins, such as m-opioid receptors
(Parolaro et al., 1990; Chan et al., 1995), mediate a tonic inhibi-
tion of the activity of tuberoinfundibular dopamine neurons in
the hypothalamus (Callahan et al., 1996). Therefore, pertussis
toxin-induced inactivation of Gi/o-proteins coupled to the
m-opioid receptors in the hypothalamus could produce a disinhi-
bition of dopaminergic neurons and result in increased release of
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dopamine. Increased dopamine levels in the anterior pituitary
gland inhibit the secretion of prolactin, regardless of the presence
of other stimuli that increase its secretion (Pilotte and Porter,
1981; Callahan et al., 1996). This explanation is consistent with
the observation that pertussis toxin treatment reduced basal pro-
lactin levels.
In conclusion, the present study provides the first in vivo evi-
dence demonstrating that Gz-proteins couple 5-HT1A receptors
in the hypothalamus to effector systems that trigger the secretion
of ACTH and oxytocin. These data suggest that the ACTH and
oxytocin responses to 5-HT1A agonists can be used as peripheral
markers of alterations in hypothalamic 5-HT1A receptors signal
transduction via altered coupling of Gz-protein.
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